Literature DB >> 27836952

Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis.

Raphael Borie1,2, Laure Tabèze1,2, Gabriel Thabut2,3, Hilario Nunes4, Vincent Cottin5, Sylvain Marchand-Adam6, Grégoire Prevot7, Abdellatif Tazi8, Jacques Cadranel9, Herve Mal3, Lidwine Wemeau-Stervinou10, Anne Bergeron Lafaurie8, Dominique Israel-Biet11, Clement Picard12, Martine Reynaud Gaubert13, Stephane Jouneau14, Jean-Marc Naccache9, Julie Mankikian6, Christelle Ménard15, Jean-François Cordier5, Dominique Valeyre4, Marion Reocreux15, Bernard Grandchamp15, Patrick Revy16, Caroline Kannengiesser15,17, Bruno Crestani18,2,17.   

Abstract

Telomerase reverse transcriptase (TERT) or telomerase RNA (TERC) gene mutation is a major monogenic cause of pulmonary fibrosis. Sequencing of TERT/TERC genes is proposed to patients with familial pulmonary fibrosis. Little is known about the possible predictors of this mutation and its impact on prognosis.We retrospectively analysed all the genetic diagnoses made between 2007-2014 in patients with pulmonary fibrosis. We evaluated the prevalence of TERT/TERC disease-associated variant (DAV), factors associated with a DAV, and the impact of the DAV on survival.237 patients with pulmonary fibrosis (153 with familial pulmonary fibrosis, 84 with telomere syndrome features without familial pulmonary fibrosis) were tested for TERT/TERC DAV. DAV was diagnosed in 40 patients (16.8%), including five with non-idiopathic interstitial pneumonia. Prevalence of TERT/TERC DAV did not significantly differ between patients with familial pulmonary fibrosis or with only telomere syndrome features (18.2% versus 16.4%). Young age, red blood cell macrocytosis, and low platelet count were associated with the presence of DAV; the probability of DAV was increased for patients 40-60 years. Transplant-free survival was lower with than without TERT/TERC DAV (4.2 versus 7.2 years; p=0.046).TERT/TERC DAV were associated with specific clinical and biological features and reduced transplant-free survival.
Copyright ©ERS 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27836952     DOI: 10.1183/13993003.02115-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  29 in total

1.  MUC5B variant is associated with visually and quantitatively detected preclinical pulmonary fibrosis.

Authors:  Susan K Mathai; Stephen Humphries; Jonathan A Kropski; Timothy S Blackwell; Julia Powers; Avram D Walts; Cheryl Markin; Julia Woodward; Jonathan H Chung; Kevin K Brown; Mark P Steele; James E Loyd; Marvin I Schwarz; Tasha Fingerlin; Ivana V Yang; David A Lynch; David A Schwartz
Journal:  Thorax       Date:  2019-09-26       Impact factor: 9.139

Review 2.  Telomeres in Interstitial Lung Disease: The Short and the Long of It.

Authors:  Andrew M Courtwright; Souheil El-Chemaly
Journal:  Ann Am Thorac Soc       Date:  2019-02

3.  Whole-Exome Sequencing Insights into Adult Pulmonary Fibrosis. Repeating the Telomere Theme.

Authors:  Christine Kim Garcia
Journal:  Am J Respir Crit Care Med       Date:  2017-07-01       Impact factor: 21.405

Review 4.  Noncoding RNAs Controlling Telomere Homeostasis in Senescence and Aging.

Authors:  Martina Rossi; Myriam Gorospe
Journal:  Trends Mol Med       Date:  2020-02-28       Impact factor: 11.951

Review 5.  Insights from human genetic studies of lung and organ fibrosis.

Authors:  Christine Kim Garcia
Journal:  J Clin Invest       Date:  2018-01-02       Impact factor: 14.808

6.  Familial pulmonary fibrosis: a world without frontiers.

Authors:  Raphael Borie; Bruno Crestani
Journal:  J Bras Pneumol       Date:  2019-10-07       Impact factor: 2.624

Review 7.  An update on the biology and management of dyskeratosis congenita and related telomere biology disorders.

Authors:  Marena R Niewisch; Sharon A Savage
Journal:  Expert Rev Hematol       Date:  2019-09-10       Impact factor: 2.819

Review 8.  Familial Pulmonary Fibrosis: Genetic Features and Clinical Implications.

Authors:  David Zhang; Chad A Newton
Journal:  Chest       Date:  2021-06-26       Impact factor: 9.410

9.  Diverse Pathological Findings of Interstitial Lung Disease in a Patient with Dyskeratosis Congenita.

Authors:  Ryota Otoshi; Tomohisa Baba; Ryota Shintani; Hideya Kitamura; Yukie Yamaguchi; Haruka Hamanoue; Takeshi Mizuguchi; Naomichi Matsumoto; Koji Okudela; Tamiko Takemura; Takashi Ogura
Journal:  Intern Med       Date:  2020-11-16       Impact factor: 1.271

10.  A Case Series of TERC Variant Telomere Biology Disorders in Unrelated Families From Atlantic Canada.

Authors:  Amye M Harrigan; Shelley MacDonald; Bruce Crooks; Sarah Dyack; Amy M Trottier
Journal:  J Hematol       Date:  2021-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.